文献速递消化系统肿瘤

ROR2调控胰腺肿瘤形成与腺癌中的细胞可塑性

ROR2 Regulates Cellular Plasticity in Pancreatic Neoplasia and Adenocarcinoma.
PubMed 文献 · Cancer Discov · 2024-01-01

该研究发现正常腺泡细胞分化由转录因子PDX1维持,抑制广泛的胃细胞身份;ROR2是胰腺肿瘤中胃化生样身份的标记。在小鼠胰腺肿瘤模型中敲除Ror2促进向胃小凹细胞身份转换,并在经典亚型PDAC进展中持续存在。在人和小鼠胰腺癌中,ROR2活性持续拮抗胃小凹细胞身份,强烈促进上皮间质转化,赋予KRAS抑制剂耐药和对AKT抑制的脆弱性。

要点

  • PDX1维持的腺泡分化抑制胃细胞身份,该身份在化生、肿瘤形成及经典亚型PDAC中保留。
  • ROR2标记胰腺肿瘤中的胃化生样身份,敲除Ror2促进向胃小凹细胞身份转换。
  • ROR2活性促进上皮间质转化,赋予KRAS抑制剂耐药和对AKT抑制的脆弱性。

核心结论

  • ROR2是胰腺癌前病变和胰腺癌中细胞身份的重要调控因子,驱动侵袭性PDAC表型并赋予KRAS抑制剂耐药,提示靶向ROR2可能增强对新一代靶向治疗的敏感性。

研究设计与样本

  • 研究使用小鼠和人的胰腺肿瘤模型,包括胰腺肿瘤发生小鼠模型,进行Ror2基因敲除实验。

主要发现

  • 正常腺泡细胞分化由转录因子PDX1维持,抑制广泛的胃细胞身份,该身份在化生、肿瘤形成和PDAC经典亚型中保持。
  • ROR2被鉴定为胰腺肿瘤中胃化生样身份的标记。
  • 在小鼠胰腺肿瘤发生模型中敲除Ror2促进向胃小凹细胞身份转换,该身份在进展至PDAC经典亚型中大部分持续存在。
  • 在人和小鼠胰腺癌中,ROR2活性持续拮抗胃小凹细胞身份,强烈促进上皮间质转化,赋予KRAS抑制剂耐药和对AKT抑制的脆弱性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cellular plasticity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) starting from the conversion of normal cells into precancerous lesions, to the progression of carcinoma subtypes associated with aggressiveness and therapeutic response. We discovered that normal acinar cell differentiation, maintained by the transcription factor PDX1, suppresses a broad gastric cell identity that is maintained in metaplasia, neoplasia, and the classical subtype of PDAC in a mouse and human. We identified the receptor tyrosine kinase ROR2 as marker of a gastric metaplasia-like identity in pancreas neoplasms. Ablation of Ror2 in a mouse model of pancreatic tumorigenesis promoted a switch to a gastric pit cell identity that largely persisted through progression to the classical subtype of PDAC. In both human and mouse pancreatic cancer, ROR2 activity continued to antagonize the gastric pit cell identity, strongly promoting an epithelial to mesenchymal transition, conferring resistance to KRAS inhibition, and vulnerability to AKT inhibition. Significance: We discovered the receptor tyrosine kinase ROR2 as an important regulator of cellular identity in pancreatic precancerous lesions and pancreatic cancer. ROR2 drives an aggressive PDAC phenotype and confers resistance to KRAS inhibitors, suggesting that targeting ROR2 will enhance sensitivity to this new generation of targeted therapies. See related commentary by Marasco and Misale, p. 2018.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Benitz S, Steep A, Nasser MM, et al. ROR2 Regulates Cellular Plasticity in Pancreatic Neoplasia and Adenocarcinoma. Cancer Discov. 2024. PMID: 38975886. doi:10.1158/2159-8290.CD-24-0137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。